New brain cancer drug combo enters first human tests

NCT ID NCT07185880

Recruiting now Disease control Sponsor: Myosin Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MT-125 given together with standard radiation for people newly diagnosed with a fast-growing brain tumor called glioblastoma. The main goals are to find a safe dose and understand side effects. About 36 adults aged 18 and older with a specific type of glioblastoma (IDH wild-type, MGMT-unmethylated) can join. This is the first time MT-125 is tested in humans, so its safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM)

Contacts and locations

Show contact details

Locations

Mayo Clinic Hospital
RECRUITING

Phoenix, Arizona, 85054, United States

Contact Email: •••••@•••••
Mayo Clinic Hospital
RECRUITING

Jacksonville, Florida, 32224, United States

Contact Email: •••••@•••••
Mayo Clinic Hospital
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.